BPC 157: Separating Fact from Fiction in Soft Tissue Injury Treatment Erik Schraga posted on the topic LinkedIn The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York The Peptide Craze Ground Truths Multifunctionality and Possible Medical Application of the BPC 157 PeptideLiterature and Patent Review It's About to Be Hot Peptide Summer GQ FDA's Overreach on Compounded Peptides